IFNA2 (Ukrainian Wikipedia)

Analysis of information sources in references of the Wikipedia article "IFNA2" in Ukrainian language version.

refsWebsite

Global rank Ukrainian rank

41nih.gov

4^th place

5^th place

28doi.org

2^nd place

4^th place

3semanticscholar.org

11^th place

964^th place

3archive.org

6^th place

2harvard.edu

18^th place

74^th place

1genenames.org

low place

1,037^th place

1web.archive.org

1^st place

1uniprot.org

5,673^rd place

770^th place

1zenodo.org

621^st place

1,216^th place

1yalebooks.com

low place

archive.org (Global: 6^th place; Ukrainian: 6^th place)

Qi Z, Nie P, Secombes CJ, Zou J (May 2010). Intron-containing type I and type III IFN coexist in amphibians: refuting the concept that a retroposition event gave rise to type I IFNs. J. Immunol. 184 (9): 5038—46. doi:10.4049/jimmunol.0903374. PMID 20357248.
Génin P, Lin R, Hiscott J, Civas A (Jun 2009). Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol Cell Biol. 29 (12): 3435—50. doi:10.1128/MCB.01805-08. PMC 2698742. PMID 19349300.
Trinchieri G (Sep 2010). Type I interferon: friend or foe?. J Exp Med. 207 (10): 2053—63. doi:10.1084/jem.20101664. PMC 2947062. PMID 20837696.

doi.org (Global: 2^nd place; Ukrainian: 4^th place)

Gresser I (2015). On intuition and the discovery of interferon. Cytokine Growth Factor Rev. 26 (2): 99—101. doi:10.1016/j.cytogfr.2014.11.006. PMID 25547990.
Pestka S, Krause CD, Walter MR (Dec 2004). Interferons, interferon-like cytokines, and their receptors. Immunological Reviews. 202: 8—32. doi:10.1111/j.0105-2896.2004.00204.x. PMID 15546383. S2CID 13600136.
Díaz MO, Pomykala HM, Bohlander SK, Maltepe E, Malik K, Brownstein B, Olopade OI (Aug 1994). Structure of the human type-I interferon gene cluster determined from a YAC clone contig. Genomics. 22 (3): 540—52. doi:10.1006/geno.1994.1427. PMID 8001965.
Qi Z, Nie P, Secombes CJ, Zou J (May 2010). Intron-containing type I and type III IFN coexist in amphibians: refuting the concept that a retroposition event gave rise to type I IFNs. J. Immunol. 184 (9): 5038—46. doi:10.4049/jimmunol.0903374. PMID 20357248.
Klaus W, Gsell B, Labhardt AM, Wipf B, Senn H (Dec 1997). The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution. J Mol Biol. 274 (4): 661—75. doi:10.1006/jmbi.1997.1396. PMID 9417943.
Radhakrishnan R, Walter LJ, Hruza A, Reichert P, Trotta PP, Nagabhushan TL, Walter MR (Dec 1996). Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography. Structure. 4 (12): 1453—63. doi:10.1016/s0969-2126(96)00152-9. PMID 8994971.
von Gabain A, Lundgren E, Ohlsson M, Holmgren E, Josephsson S, Alkan SS (Jun 1990). Three human interferon-alpha 2 subvariants disclose structural and functional differences. Eur J Biochem. 190 (2): 257—61. doi:10.1111/j.1432-1033.1990.tb15570.x. PMID 1694761.
Génin P, Lin R, Hiscott J, Civas A (Jun 2009). Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol Cell Biol. 29 (12): 3435—50. doi:10.1128/MCB.01805-08. PMC 2698742. PMID 19349300.
Honda K, Yanai H, Takaoka A, Taniguchi T (Nov 2005). Regulation of the type I IFN induction: a current view. Int Immunol. 17 (11): 1367—78. doi:10.1093/intimm/dxh318. PMID 16214811.
Weissmann, Charles (2001), Buckel, Peter (ред.), Recombinant interferon – the 20th anniversary, Recombinant Protein Drugs, Milestones in Drug Therapy (англ.), Birkhäuser, с. 3—41, doi:10.1007/978-3-0348-8346-7_1, ISBN 978-3-0348-8346-7
Tomasello E, Pollet E, Vu Manh TP, Uzé G, Dalod M (Oct 2014). Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types. Front Immunol. 5: 526. doi:10.3389/fimmu.2014.00526. PMC 4214202. PMID 25400632.
Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, Lee C, Yarden G, Vleck SE, Glenn JS, Nolan GP, Piehler J, Schreiber G, Garcia KC (Aug 2011). Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell. 146 (4): 621—32. doi:10.1016/j.cell.2011.06.048. PMC 3166218. PMID 21854986.
Platanias LC (May 2005). Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 5 (5): 375—86. doi:10.1038/nri1604. PMID 15864272. S2CID 1472195.
Uzé G, Schreiber G, Piehler J, Pellegrini S (2007). The receptor of the type I interferon family. Curr Top Microbiol Immunol. Current Topics in Microbiology and Immunology. 316: 71—95. doi:10.1007/978-3-540-71329-6_5. ISBN 978-3-540-71328-9. PMID 17969444.
Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR (Dec 2007). Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 6 (12): 975—90. doi:10.1038/nrd2422. PMC 7097588. PMID 18049472.
Gajewski TF, Corrales L (2015). New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev. 26 (2): 175—8. doi:10.1016/j.cytogfr.2015.01.001. PMC 4387009. PMID 25630967.
Gough DJ, Messina NL, Clarke CJ, Johnstone RW, Levy DE (Feb 2012). Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity. 36 (2): 166—74. doi:10.1016/j.immuni.2012.01.011. PMC 3294371. PMID 22365663.
McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A (Feb 2015). Type I interferons in infectious disease. Nat Rev Immunol. 15 (2): 87—103. doi:10.1038/nri3787. PMC 7162685. PMID 25614319.
Trinchieri G (Sep 2010). Type I interferon: friend or foe?. J Exp Med. 207 (10): 2053—63. doi:10.1084/jem.20101664. PMC 2947062. PMID 20837696.
Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD (Sep 2011). Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 208 (10): 1989—2003. doi:10.1084/jem.20101158. PMC 3182061. PMID 21930769.
Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF (Sep 2011). Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 208 (10): 2005—16. doi:10.1084/jem.20101159. PMC 3182064. PMID 21930765.
Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, Auh SL (Apr 2011). The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 71 (7): 2488—96. doi:10.1158/0008-5472.CAN-10-2820. PMC 3070872. PMID 21300764.
Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW, Smyth MJ (Apr 2011). Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 108 (17): 7142—7. Bibcode:2011PNAS..108.7142S. doi:10.1073/pnas.1016569108. PMC 3084100. PMID 21482773.
Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, Gabriele L, Proietti E, Bracci L (Feb 2011). Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 71 (3): 768—78. doi:10.1158/0008-5472.CAN-10-2788. PMID 21156650.
Lichtman EI, Helfgott SM, Kriegel MA (Jun 2012). Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha. Clin Immunol. 143 (3): 210—21. doi:10.1016/j.clim.2012.03.005. PMC 3358492. PMID 22525889.
Antonelli G, Scagnolari C, Moschella F, Proietti E (2015). Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use. Cytokine Growth Factor Rev. 26 (2): 121—31. doi:10.1016/j.cytogfr.2014.12.006. PMC 7108252. PMID 25578520.
Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G (Dec 2005). Side effects of interferon-alpha therapy. Pharm World Sci. 27 (6): 423—31. doi:10.1007/s11096-005-1319-7. PMID 16341948. S2CID 20976432.
Garcin G, Paul F, Staufenbiel M, Bordat Y, Van der Heyden J, Wilmes S, Cartron G, Apparailly F, De Koker S, Piehler J, Tavernier J, Uzé G (2014). High efficiency cell-specific targeting of cytokine activity. Nat. Commun. 5: 3016. Bibcode:2014NatCo...5.3016G. doi:10.1038/ncomms4016. PMID 24398568.

genenames.org (Global: low place; Ukrainian: 1,037^th place)

HUGO Gene Nomenclature Commitee, HGNC:5423 (англ.) . Процитовано 7 вересня 2017.{{cite web}}: Обслуговування CS1: Сторінки з параметром url-status, але без параметра archive-url (посилання)

harvard.edu (Global: 18^th place; Ukrainian: 74^th place)

ui.adsabs.harvard.edu

Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW, Smyth MJ (Apr 2011). Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 108 (17): 7142—7. Bibcode:2011PNAS..108.7142S. doi:10.1073/pnas.1016569108. PMC 3084100. PMID 21482773.
Garcin G, Paul F, Staufenbiel M, Bordat Y, Van der Heyden J, Wilmes S, Cartron G, Apparailly F, De Koker S, Piehler J, Tavernier J, Uzé G (2014). High efficiency cell-specific targeting of cytokine activity. Nat. Commun. 5: 3016. Bibcode:2014NatCo...5.3016G. doi:10.1038/ncomms4016. PMID 24398568.

nih.gov (Global: 4^th place; Ukrainian: 5^th place)

pubmed.ncbi.nlm.nih.gov

Gresser I (2015). On intuition and the discovery of interferon. Cytokine Growth Factor Rev. 26 (2): 99—101. doi:10.1016/j.cytogfr.2014.11.006. PMID 25547990.
Pestka S, Krause CD, Walter MR (Dec 2004). Interferons, interferon-like cytokines, and their receptors. Immunological Reviews. 202: 8—32. doi:10.1111/j.0105-2896.2004.00204.x. PMID 15546383. S2CID 13600136.
Díaz MO, Pomykala HM, Bohlander SK, Maltepe E, Malik K, Brownstein B, Olopade OI (Aug 1994). Structure of the human type-I interferon gene cluster determined from a YAC clone contig. Genomics. 22 (3): 540—52. doi:10.1006/geno.1994.1427. PMID 8001965.
Qi Z, Nie P, Secombes CJ, Zou J (May 2010). Intron-containing type I and type III IFN coexist in amphibians: refuting the concept that a retroposition event gave rise to type I IFNs. J. Immunol. 184 (9): 5038—46. doi:10.4049/jimmunol.0903374. PMID 20357248.
Klaus W, Gsell B, Labhardt AM, Wipf B, Senn H (Dec 1997). The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution. J Mol Biol. 274 (4): 661—75. doi:10.1006/jmbi.1997.1396. PMID 9417943.
Radhakrishnan R, Walter LJ, Hruza A, Reichert P, Trotta PP, Nagabhushan TL, Walter MR (Dec 1996). Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography. Structure. 4 (12): 1453—63. doi:10.1016/s0969-2126(96)00152-9. PMID 8994971.
von Gabain A, Lundgren E, Ohlsson M, Holmgren E, Josephsson S, Alkan SS (Jun 1990). Three human interferon-alpha 2 subvariants disclose structural and functional differences. Eur J Biochem. 190 (2): 257—61. doi:10.1111/j.1432-1033.1990.tb15570.x. PMID 1694761.
Génin P, Lin R, Hiscott J, Civas A (Jun 2009). Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol Cell Biol. 29 (12): 3435—50. doi:10.1128/MCB.01805-08. PMC 2698742. PMID 19349300.
Honda K, Yanai H, Takaoka A, Taniguchi T (Nov 2005). Regulation of the type I IFN induction: a current view. Int Immunol. 17 (11): 1367—78. doi:10.1093/intimm/dxh318. PMID 16214811.
Tomasello E, Pollet E, Vu Manh TP, Uzé G, Dalod M (Oct 2014). Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types. Front Immunol. 5: 526. doi:10.3389/fimmu.2014.00526. PMC 4214202. PMID 25400632.
Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, Lee C, Yarden G, Vleck SE, Glenn JS, Nolan GP, Piehler J, Schreiber G, Garcia KC (Aug 2011). Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell. 146 (4): 621—32. doi:10.1016/j.cell.2011.06.048. PMC 3166218. PMID 21854986.
Platanias LC (May 2005). Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 5 (5): 375—86. doi:10.1038/nri1604. PMID 15864272. S2CID 1472195.
Uzé G, Schreiber G, Piehler J, Pellegrini S (2007). The receptor of the type I interferon family. Curr Top Microbiol Immunol. Current Topics in Microbiology and Immunology. 316: 71—95. doi:10.1007/978-3-540-71329-6_5. ISBN 978-3-540-71328-9. PMID 17969444.
Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR (Dec 2007). Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 6 (12): 975—90. doi:10.1038/nrd2422. PMC 7097588. PMID 18049472.
Gajewski TF, Corrales L (2015). New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev. 26 (2): 175—8. doi:10.1016/j.cytogfr.2015.01.001. PMC 4387009. PMID 25630967.
Gough DJ, Messina NL, Clarke CJ, Johnstone RW, Levy DE (Feb 2012). Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity. 36 (2): 166—74. doi:10.1016/j.immuni.2012.01.011. PMC 3294371. PMID 22365663.
McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A (Feb 2015). Type I interferons in infectious disease. Nat Rev Immunol. 15 (2): 87—103. doi:10.1038/nri3787. PMC 7162685. PMID 25614319.
Trinchieri G (Sep 2010). Type I interferon: friend or foe?. J Exp Med. 207 (10): 2053—63. doi:10.1084/jem.20101664. PMC 2947062. PMID 20837696.
Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD (Sep 2011). Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 208 (10): 1989—2003. doi:10.1084/jem.20101158. PMC 3182061. PMID 21930769.
Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF (Sep 2011). Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 208 (10): 2005—16. doi:10.1084/jem.20101159. PMC 3182064. PMID 21930765.
Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, Auh SL (Apr 2011). The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 71 (7): 2488—96. doi:10.1158/0008-5472.CAN-10-2820. PMC 3070872. PMID 21300764.
Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW, Smyth MJ (Apr 2011). Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 108 (17): 7142—7. Bibcode:2011PNAS..108.7142S. doi:10.1073/pnas.1016569108. PMC 3084100. PMID 21482773.
Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, Gabriele L, Proietti E, Bracci L (Feb 2011). Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 71 (3): 768—78. doi:10.1158/0008-5472.CAN-10-2788. PMID 21156650.
Lichtman EI, Helfgott SM, Kriegel MA (Jun 2012). Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha. Clin Immunol. 143 (3): 210—21. doi:10.1016/j.clim.2012.03.005. PMC 3358492. PMID 22525889.
Antonelli G, Scagnolari C, Moschella F, Proietti E (2015). Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use. Cytokine Growth Factor Rev. 26 (2): 121—31. doi:10.1016/j.cytogfr.2014.12.006. PMC 7108252. PMID 25578520.
Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G (Dec 2005). Side effects of interferon-alpha therapy. Pharm World Sci. 27 (6): 423—31. doi:10.1007/s11096-005-1319-7. PMID 16341948. S2CID 20976432.
Garcin G, Paul F, Staufenbiel M, Bordat Y, Van der Heyden J, Wilmes S, Cartron G, Apparailly F, De Koker S, Piehler J, Tavernier J, Uzé G (2014). High efficiency cell-specific targeting of cytokine activity. Nat. Commun. 5: 3016. Bibcode:2014NatCo...5.3016G. doi:10.1038/ncomms4016. PMID 24398568.

ncbi.nlm.nih.gov

Génin P, Lin R, Hiscott J, Civas A (Jun 2009). Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol Cell Biol. 29 (12): 3435—50. doi:10.1128/MCB.01805-08. PMC 2698742. PMID 19349300.
Tomasello E, Pollet E, Vu Manh TP, Uzé G, Dalod M (Oct 2014). Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types. Front Immunol. 5: 526. doi:10.3389/fimmu.2014.00526. PMC 4214202. PMID 25400632.
Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, Lee C, Yarden G, Vleck SE, Glenn JS, Nolan GP, Piehler J, Schreiber G, Garcia KC (Aug 2011). Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell. 146 (4): 621—32. doi:10.1016/j.cell.2011.06.048. PMC 3166218. PMID 21854986.
Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR (Dec 2007). Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 6 (12): 975—90. doi:10.1038/nrd2422. PMC 7097588. PMID 18049472.
Gajewski TF, Corrales L (2015). New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev. 26 (2): 175—8. doi:10.1016/j.cytogfr.2015.01.001. PMC 4387009. PMID 25630967.
Gough DJ, Messina NL, Clarke CJ, Johnstone RW, Levy DE (Feb 2012). Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity. 36 (2): 166—74. doi:10.1016/j.immuni.2012.01.011. PMC 3294371. PMID 22365663.
McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A (Feb 2015). Type I interferons in infectious disease. Nat Rev Immunol. 15 (2): 87—103. doi:10.1038/nri3787. PMC 7162685. PMID 25614319.
Trinchieri G (Sep 2010). Type I interferon: friend or foe?. J Exp Med. 207 (10): 2053—63. doi:10.1084/jem.20101664. PMC 2947062. PMID 20837696.
Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD (Sep 2011). Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 208 (10): 1989—2003. doi:10.1084/jem.20101158. PMC 3182061. PMID 21930769.
Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF (Sep 2011). Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 208 (10): 2005—16. doi:10.1084/jem.20101159. PMC 3182064. PMID 21930765.
Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, Auh SL (Apr 2011). The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 71 (7): 2488—96. doi:10.1158/0008-5472.CAN-10-2820. PMC 3070872. PMID 21300764.
Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW, Smyth MJ (Apr 2011). Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 108 (17): 7142—7. Bibcode:2011PNAS..108.7142S. doi:10.1073/pnas.1016569108. PMC 3084100. PMID 21482773.
Lichtman EI, Helfgott SM, Kriegel MA (Jun 2012). Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha. Clin Immunol. 143 (3): 210—21. doi:10.1016/j.clim.2012.03.005. PMC 3358492. PMID 22525889.
Antonelli G, Scagnolari C, Moschella F, Proietti E (2015). Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use. Cytokine Growth Factor Rev. 26 (2): 121—31. doi:10.1016/j.cytogfr.2014.12.006. PMC 7108252. PMID 25578520.

semanticscholar.org (Global: 11^th place; Ukrainian: 964^th place)

api.semanticscholar.org

Pestka S, Krause CD, Walter MR (Dec 2004). Interferons, interferon-like cytokines, and their receptors. Immunological Reviews. 202: 8—32. doi:10.1111/j.0105-2896.2004.00204.x. PMID 15546383. S2CID 13600136.
Platanias LC (May 2005). Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 5 (5): 375—86. doi:10.1038/nri1604. PMID 15864272. S2CID 1472195.
Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G (Dec 2005). Side effects of interferon-alpha therapy. Pharm World Sci. 27 (6): 423—31. doi:10.1007/s11096-005-1319-7. PMID 16341948. S2CID 20976432.

uniprot.org (Global: 5,673^rd place; Ukrainian: 770^th place)

UniProt, P01563 (англ.) . Архів оригіналу за 20 березня 2017. Процитовано 7 вересня 2017.

web.archive.org (Global: 1^st place; Ukrainian: 1^st place)

UniProt, P01563 (англ.) . Архів оригіналу за 20 березня 2017. Процитовано 7 вересня 2017.

yalebooks.com (Global: low place; Ukrainian: low place)

blog.yalebooks.com

Cuba's Contribution to Combating COVID-19. 12 березня 2020.

zenodo.org (Global: 621^st place; Ukrainian: 1,216^th place)

McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A (Feb 2015). Type I interferons in infectious disease. Nat Rev Immunol. 15 (2): 87—103. doi:10.1038/nri3787. PMC 7162685. PMID 25614319.

IFNA2 (Ukrainian Wikipedia)

archive.org (Global: 6th place; Ukrainian: 6th place)

doi.org (Global: 2nd place; Ukrainian: 4th place)

genenames.org (Global: low place; Ukrainian: 1,037th place)

harvard.edu (Global: 18th place; Ukrainian: 74th place)